Clinical trials: Microparticles
Acne Vulgaris
Sebacia Postmarket Study of Real-World Use
Postmarket study of Sebacia Microparticles treatment during adoption into clinical use for patients with mild to moderate inflammatory acne vulgaris.
- Trial name
- NCT03818555
- Testing
- Sebacia Microparticles Treatment
- Where
- 6 sites in United States
- Volunteers
- 125 people
- Sponsor
- Sebacia, Inc.
Ruptured Cerebral Aneurysm, Ruptured Berry Aneurysm
Safety and Tolerability Study of EG-1962 in Aneurysmal Subarachnoid Hemorrhage
Phase 1/2a Multicenter, Controlled, Randomized, Open Label, Dose Escalation, Safety, Tolerability, and Pharmacokinetic Study Comparing EG-1962 and Nimodipine in Patients with Aneurysmal Subarachnoid Hemorrhage
- Trial name
- NEWTON (NCT01893190)
- Testing
- Nimodipine, Nimodipine Microparticles
- Where
- 23 sites in United States, Canada and 2 more
- Volunteers
- 73 people
- Sponsor
- Edge Therapeutics Inc
Seasonal Allergic Rhinitis
Phase I/IIa Study on Chitin Microparticles in Subjects Suffering From Allergic Rhinitis
Chitin microparticles (CMP) has been demonstrated in animal studies that have modelled allergic rhinitis to be effective against a wide range of common respiratory allergens. It is an immuneenhancer.
- Trial name
- NCT00443495
- Testing
- Chitin microparticles by nasal route
- Volunteers
- 24 people
- Sponsor
- CMP Therapeutics Ltd
Inflammatory Acne Vulgaris
Pivotal Study of Sebacia Microparticles in the Treatment of Acne Vulgaris
Prospective, randomized multicenter study to examine the safety and effectiveness of Sebacia microparticles with or without laser in the treatment of moderate to moderately-severe inflammatory acne vulgaris
- Trial name
- NCT02217228
- Testing
- Sebacia microparticles and laser, Vehicle suspension and laser, Sebacia microparticles without laser
- Where
- 19 sites in United States
- Volunteers
- 394 people
- Sponsor
- Sebacia, Inc.
Acne Vulgaris
Non-Significant Risk Study of Sebacia Microparticles in the Treatment of Facial Acne Vulgaris
Prospective, randomized, controlled, parallel group clinical study with blinded assessment evaluating Sebacia Microparticles (SM) with Nd:Yag laser in facial inflammatory acne vulgaris
- Trial name
- NCT03303170
- Testing
- Sebacia Microparticles, Nd:Yag Laser
- Where
- 11 sites in United States
- Volunteers
- 168 people
- Sponsor
- Sebacia, Inc.
Intestinal Obstruction, Carcinoma
Efficacy and Safety of Lanreotide Microparticles as Palliative Treatment in Peritoneal Carcinomatosis
The purpose of this study is to determine whether lanreotide 30mg microparticles are effective in the relief of clinical symptoms due to small bowel obstruction in inoperable patients with peritoneal carcinomatosis.
- Conditions
- Intestinal Obstruction, Carcinoma, Peritoneal Neoplasms
- Trial name
- NCT00216372
- Testing
- Lanreotide (microparticle formulation)
- Where
- 53 sites in Belgium, France and 1 more
- Volunteers
- 80 people
- Sponsor
- Ipsen
Acne Vulgaris
Multiple Arm Study of Sebacia Microparticles in the Treatment of Acne Vulgaris
Prospective, multicenter study with multiple arms to examine the safety and effectiveness of the Sebacia Acne Treatment System for the treatment of acne vulgaris.
- Trial name
- NCT02219074
- Testing
- Sebacia microparticle and laser treatment, Vehicle and laser treatment
- Where
- 2 sites in Poland
- Volunteers
- 350 people
- Sponsor
- Sebacia, Inc.
Achilles Tendinopathy
A Study to Investigate the Safety, Tolerability and Preliminary Efficacy of NGI226 Microparticles in Patients With Achilles Tendinopathy
The purpose of this study is to measure local and systemic safety and tolerability as well as improvement of Achilles tendon mechanical properties after a single peritendon injection of NGI226 MP in comparison to placebo MP in…
- Trial name
- NCT05592990
- Testing
- NGI226
- Where
- 7 sites in United States, France and 1 more
- Volunteers
- 45 people
- Sponsor
- Novartis Pharmaceuticals
Facial Acne Vulgaris
A Study to Evaluate Sebacia Microparticles in Patients With Inflammatory Acne Vulgaris
This study is proposed to evaluate Sebacia Microparticle treatment in patients with facial inflammatory acne vulgaris.
- Trial name
- NCT02758041
- Testing
- Sebacia Microparticles
- Where
- 3 sites in Denmark, Switzerland
- Volunteers
- 85 people
- Sponsor
- Sebacia, Inc.